QXO Shorts Retreat as Stock Outpaces Peers

QXO gained 10.1% over the past week, putting it ahead of the median gain of 5.7% across its closest building products peers and marking a sharp reversal for a stock that had fallen nearly 40% year to date. Short interest at 17.7% of the free float remains well above the levels seen across comparable distributors such as BCC, which fell 1.6% on the week, and SITE, which added 8.4%.

The short position has been declining, and the pace of that retreat accelerated sharply this week. Shares short dropped 10.4% in a single session on November 3, bringing the 30-day decline to around 4%. At roughly 119 million shares, the position has unwound from a peak above 154 million in late October, its highest reading of the recent stretch. The ORTEX short score, a composite of lending and positioning signals, eased to 71.5 from 76.4 a week ago, though it remains elevated. Borrowing costs nudged higher to 0.94%, up 18% on the week and 45% over the past month, which is consistent with some ongoing demand for new short positions even as the aggregate count falls. Availability has loosened relative to mid-October lows, with roughly 81% of shares-available-to-borrow still unlent, so there is no structural squeeze in the lending market at present.

Options positioning is calm and tilted toward calls. The put/call ratio at 0.34 is marginally above its 20-day average of 0.33, well within one standard deviation of normal, and far below the 52-week high of 0.83. That low reading reflects steady call-side interest rather than any defensive hedging, consistent with a market that is covering shorts and not yet replacing them with puts.

The Street remains constructive but has been cutting targets. Wells Fargo trimmed its price target twice in October, from $18 to $16 and then again to $15, while maintaining an Overweight rating. Truist cut its target from $26 to $15 in early October, and RBC moved from $27 to $18, both holding positive ratings. Morgan Stanley reinstated coverage in August with an Overweight and a $35 target, now looking stretched against the current $11.71 price. The mean target across the analyst community at the time of the most recent data stands near $24, implying substantial upside on paper, but the direction of travel on targets has been unambiguously downward. Factor scores are weak across the board: the short score rank sits at the 3rd percentile of the universe, sector score at the 5th, and earnings yield at the 21st, with EPS surprise at the 4th percentile. The EV/EBITDA multiple at 5.9x has expanded by roughly 0.4 turns over the past 30 days, tracking the modest price recovery.

The ownership picture carries two headline items. Bradley Jacobs, the founder and driving force behind QXO's consolidation strategy, filed a 13D/A showing his stake declined from 49% to 35.9% as of April. That is still a commanding position, but the reduction is worth noting in a company where the investment thesis is tightly bound to one operator's execution. Jared Kushner, also on the register as a 13D filer, last disclosed a stake of 4.9%, down from 6.3%. On the institutional side, Invesco added more than 12 million shares in the most recent quarter and UBS Asset Management added nearly 15 million, both meaningful additions. As always, 13D and 13G positions are event-driven disclosures around the 5% threshold, and holders who drop below that level may not file again.

Earnings are due November 13. The prior three prints produced day-one declines of 1.2%, 3.5%, and 4.2%, with the five-day return after the August report reaching negative 11.2%. The question heading into that date is whether the short retreat of the past two weeks reflects genuine conviction in the recovery, or whether it reverses if the print disappoints again.